奇正藏药(002287) - 2025 Q2 - 季度业绩

Report Overview Special Notice and Disclaimer Preliminary H1 2025 financial data, internally audited but unaudited externally, may differ from final figures, requiring investor caution - This report's data is preliminary and unaudited, potentially differing from the final report, thus investors should be aware of investment risks[3] Key Financial Data for H1 2025 Key Income Statement Metrics H1 2025 total operating revenue grew 16.36% to 1.175 billion yuan, with all key profit metrics, including non-recurring net profit, showing significant growth Key Income Statement Data for H1 2025 | Project | Current Period (yuan) | Prior Period (yuan) | Change (%) | | :--- | :--- | :--- | :--- | | Total Operating Revenue | 1,175,031,545.29 | 1,009,833,674.27 | 16.36 | | Operating Profit | 416,710,928.53 | 366,529,410.38 | 13.69 | | Total Profit | 399,917,158.99 | 365,162,439.71 | 9.52 | | Net Profit Attributable to Shareholders of Listed Company | 358,060,664.37 | 325,685,757.00 | 9.94 | | Net Profit Attributable to Shareholders of Listed Company (Excluding Non-recurring Items) | 289,110,936.50 | 227,292,243.01 | 27.20 | | Basic Earnings Per Share (yuan) | 0.6749 | 0.6143 | 9.86 | | Weighted Average Return on Net Assets | 8.58% | 8.48% | Increase by 0.10 percentage points | Key Balance Sheet Metrics At period-end, total assets increased by 0.69% to 6.837 billion yuan, while equity attributable to shareholders slightly decreased by 0.70%, and net assets per share marginally declined Key Balance Sheet Data for H1 2025 | Project | End of Current Period (yuan) | Beginning of Current Period (yuan) | Change (%) | | :--- | :--- | :--- | :--- | | Total Assets | 6,837,219,961.11 | 6,790,420,367.07 | 0.69 | | Equity Attributable to Shareholders of Listed Company | 4,036,118,607.27 | 4,064,375,038.17 | -0.70 | | Share Capital | 531,237,399.00 | 531,085,718.00 | 0.03 | | Net Assets Per Share Attributable to Shareholders of Listed Company (yuan) | 7.38 | 7.41 | -0.40 | Analysis of Operating Performance and Financial Position Revenue and Profit Growth Total operating revenue increased by 16.36% and operating profit grew by 13.69%, indicating a stable operating growth trend - Total operating revenue reached 1.175 billion yuan, a 16.36% year-over-year increase[7] - Operating profit reached 417 million yuan, a 13.69% year-over-year increase[7] Net Profit and Profitability Net profit attributable to shareholders increased by 9.94%, with non-recurring net profit surging 27.20%, indicating significant core business profitability improvement - Net profit attributable to shareholders of the listed company was 358 million yuan, a 9.94% year-over-year increase[7] - Net profit attributable to shareholders of the listed company (excluding non-recurring items) was 289 million yuan, a 27.20% year-over-year increase[7] - The company's operating performance demonstrated steady growth[7] Other Disclosures Explanation of Performance Forecast Differences No H1 2025 performance forecast was disclosed, hence no differences exist from previous performance estimates - The company did not disclose a H1 2025 performance forecast[8] Documents for Reference Investors can review the signed and sealed comparative balance sheet and income statement, and the internal audit report signed by the head of internal audit - Documents for reference include the signed and sealed comparative balance sheet and income statement[9] - Documents for reference include the internal audit report signed by the head of the internal audit department[9]